Richard C. Rosenzweig Net Worth

Mr. Richard C. Rosenzweig biography

Richard C. Rosenzweig is the Sr. VP, Gen. Counsel & Company Sec. at Angiodynamic Inc.

How old is Mr Rosenzweig?

Mr Rosenzweig is 54, he's been the Sr. VP e Gen. Counsel & Company Sec. of Angiodynamic Inc since . There are 12 older and 12 younger executives at Angiodynamic Inc. The oldest executive at Angiodynamic Inc is Dennis Meteny, 67, who is the Independent Director.

What's Mr Rosenzweig's mailing address?

Richard's mailing address filed with the SEC is C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC, 28277.

Insiders trading at Angiodynamic Inc

Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman e Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.

What does Angiodynamic Inc do?

founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie

Angiodynamic Inc executives and stock owners

Angiodynamic Inc executives and other stock owners filed with the SEC include:

• James Clemmer,
  President, Chief Executive Officer, Director
• James C. Clemmer,
  CEO, Pres & Director
• Chad Campbell,
  Senior Vice President and General Manager, Vascular Access
• Stephen Trowbridge,
  Chief Financial Officer, Executive Vice President
• Scott Centea,
  Senior Vice President, General Manager, VIT
• Stephen A. Trowbridge,
  Exec. VP & CFO
• David Helsel,
  Senior Vice President - Global Operations
• Brent Boucher,
  Senior Vice President and General Manager, Oncology/Surgery
• David D. Helsel,
  Sr. VP of Global Operations and R&D
• Warren G. Nighan,
  Sr. VP of Quality & Regulatory Affairs
• Chad T. Campbell,
  Sr. VP & GM of Vascular Access Global Bus. Unit
• Howard Donnelly,
  Independent Chairman of the Board
• Dennis Meteny,
  Independent Director
• Wesley Johnson,
  Independent Director
• Eileen Auen,
  Independent Director
• Jan Reed,
  Independent Director
• Karen Licitra,
  Independent Director
• Michael Tarnoff,
  Independent Director
• Kim Seabury,
  Senior Vice President, Information Technology
• Warren Nighan,
  Senior Vice President Quality and Regulatory Affairs
• Benjamin Davis,
  Senior Vice President Business Development
• Marna Bronfen-Moore,
  Senior Vice President of Human Resources
• Scott Centea,
  Sr. VP & GM of Vascular Interventions and Therapies & Peripheral Artery Disease
• Kim L. Seabury,
  Sr. VP of Information Technology
• Marna I. Bronfen-Moore,
  Sr. VP of HR
• Benjamin H. Davis,
  Sr. VP of Bus. Devel.
• Richard C. Rosenzweig,
  Sr. VP, Gen. Counsel & Company Sec.
• Capital Partners Gp, Llc Av...,
  
• Steve La Porte,
  Director
• Jeffrey Gold,
  Director
• Michael Greiner,
  EVP and CFO
• Sriram Venkataraman,
  Director
• Kevin J Gould,
  Director
• David F Burgstahler,
  Director
• Charles R Greiner,
  VP - Global Franchise
• Laura Piccinini,
  SVP International
• Stark Richard,
  SVP, GM - Oncology
• Robert Arthur Simpson,
  SVP/GM, Global Vascular
• David P Meyers,
  Director
• Gregory D Casciaro,
  Director
• Matthew C Kapusta,
  SVP, Business Development
• George W. Iv Bourne,
  SVP and CTO
• Stephen Mc Gill,
  SVP - General Manager
• Mark T Frost,
  EVP and CFO
• John Soto,
  VP - OUS Sales
• Lynda M. Wallace,
  SVP - Business Development
• Vincent Bucci,
  Director
• Scott J. Solano,
  Senior Vice Preisdent - CTO
• Robert D Mitchell,
  Executive VP and COO
• Shawn P Mc Carthy,
  SVP - General Manager
• Robert M Rossell,
  VP - Marketing
• Robert E Flaherty,
  Director
• William M Appling,
  VP - Research
• Brian Kunst,
  VP - Regulatory Affairs
• Peter J Graham,
  Director
• D Joseph Gersuk,
  SVP - CFO
• Paul J Shea,
  VP - Sales
• Eamonn P Hobbs,
  President and CEO
• Joseph G Gerardi,
  VP - CFO
• Alan Panzer,
  SVP, GM - Vascular
• Harold Mapes,
  VP - Operations
• Daniel Recinella,
  VP - Product Development
• Paul S Echenberg,
  Director
• Richard Scott Etlinger,
  SRVPGLOP
• Charles Thomas Orsatti,
  Director
• Joseph Devivo,
  President and CEO
• Jan Keltjens,
  President & CEO
• Howard S Stern,
  Director
• Linda B Stern,
  10% owner
• Em Inc Ez,
  10% owner
• Richard C Rosenzweig,
  SVP and General Counsel
• Dave Helsel,
  SVP Global Operations and R&D
• Lorinda Burgess,